A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer.
about
A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A benefit-risk assessment of e ...... cancer and pancreatic cancer.
@en
A benefit-risk assessment of e ...... cancer and pancreatic cancer.
@nl
type
label
A benefit-risk assessment of e ...... cancer and pancreatic cancer.
@en
A benefit-risk assessment of e ...... cancer and pancreatic cancer.
@nl
prefLabel
A benefit-risk assessment of e ...... cancer and pancreatic cancer.
@en
A benefit-risk assessment of e ...... cancer and pancreatic cancer.
@nl
P2860
P1433
P1476
A benefit-risk assessment of e ...... cancer and pancreatic cancer.
@en
P2093
Giannis Mountzios
Kostas N Syrigos
P2860
P304
P356
10.2165/11586540-000000000-00000
P577
2011-03-01T00:00:00Z
P6179
1046235533